Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research – Cancer Therapy Advisor
Cancer Therapy Advisor |
Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research
Cancer Therapy Advisor Combining 5-azacytidine (a demethylating drug) with a histone deacetylase (HDAC) inhibitor may prime non–small cell lung cancers (NSCLC) to better respond to immunotherapy, according to research published in Cell.1. The combination under study emerged … |
